Celcuity (CELC) Long-Term Debt Issuances (2024 - 2025)
Celcuity's (CELC) quarterly Long-Term Debt Issuances came in at -$7000.0 in Q4 2025, up 12.5% on a QoQ basis from -$8000.0 in Q3 2024.
Celcuity (CELC) Long-Term Debt Issuances (2024 - 2025) Analysis & Trends
Celcuity (CELC) has 2 years of Long-Term Debt Issuances data on file, last reported at -$7000.0 in Q4 2025.
- Quarterly Long-Term Debt Issuances changed N/A year-over-year to -$7000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$15000.0 (down 87.5% YoY) and the FY2025 annual result came in at $27.7 million, down 53.15% from the prior year.
- Long-Term Debt Issuances grew to -$7000.0 in Q4 2025, from -$8000.0 in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of -$7000.0 in Q4 2025 to a low of -$8000.0 in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -675,522.58 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Celcuity | 4.50 Bn | 4.50 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -7,000.00 |
| Dec 31, 2025 | -7,000.00 |
| Sep 30, 2024 | -8,000.00 |
| Sep 30, 2024 | -8,000.00 |